financetom
Business
financetom
/
Business
/
Microsoft withdrew some CoreWeave agreements over delivery issue, FT reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Microsoft withdrew some CoreWeave agreements over delivery issue, FT reports
Mar 6, 2025 12:07 AM

March 6 (Reuters) - Microsoft ( MSFT ) has moved away

from some of its agreements with cloud computing provider

CoreWeave over delivery issues and missed deadlines, the

Financial Times reported on Thursday citing unnamed sources.

Microsoft ( MSFT ) has a number of ongoing contracts with CoreWeave

that provide it with computing capacity from data centres, a

partnership which is worth billions of dollars, the newspaper

said.

Founded in 2017, CoreWeave provides access to data centers

and high-powered chips for AI workloads, mainly supplied by

Nvidia ( NVDA ).

The Nvidia ( NVDA )-backed company, which competes against cloud

providers such as Microsoft's ( MSFT ) Azure and Amazon's ( AMZN ) AWS,

has laid groundwork for what could be one of the biggest IPOs in

recent times.

CoreWeave is seeking a valuation greater than $35 billion in

its New York flotation and is likely to target raising more than

$3 billion from its share sale, Reuters has reported.

Microsoft's ( MSFT ) decision to walk away from some business with

the cloud technology provider is unrelated to a broader shift in

its own data centre plans, FT said, citing one of the people

close to the matter.

CoreWeave, Microsoft ( MSFT ) and Nvidia ( NVDA ) did not immediately respond

to Reuters' request for a comment.

On Tuesday, CoreWeave acquired AI developer platform Weights

& Biases for an undisclosed amount in a bid to extend its cloud

platform offering.

(Reporting by Angela Christy in Bengaluru; Editing by Mrigank

Dhaniwala)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TJ Maxx parent TJX raises annual profit forecast
TJ Maxx parent TJX raises annual profit forecast
Nov 19, 2025
Nov 19 (Reuters) - TJX Cos ( TJX ) raised annual profit forecast on Wednesday, anticipating that its broad sourcing strategy and seasonal inventory will attract bargain-hunting shoppers to its off-price stores. The TJ Maxx parent expects earnings per share for fiscal 2026 to be between $4.63 and $4.66, compared with its previous forecast of $4.52 to $4.57. ...
Eli Lilly to Open Gateway Labs Site in Philadelphia
Eli Lilly to Open Gateway Labs Site in Philadelphia
Nov 19, 2025
07:36 AM EST, 11/19/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Wednesday that it plans to open a new Lilly Gateway Labs site in Philadelphia. The 44,000-square-foot facility will provide fully equipped wet lab facilities for biotechs based at the site, as well as strategic scientific engagement, the company said. The company's gateway network now includes sites in...
TJ Maxx parent TJX raises annual profit forecast
TJ Maxx parent TJX raises annual profit forecast
Nov 19, 2025
(Reuters) -TJX Cos ( TJX ) raised annual profit forecast on Wednesday, anticipating that broad sourcing strategy and seasonal inventory will attract bargain-hunting shoppers to its off-price stores. Shares of the company rose about 3% in premarket trading. They have risen nearly 21% so far this year. The Framingham, Massachusetts-based company has capitalized on a seasonal shift from late-summer to...
Merck's Investigational Drug in Treatment-Naive Adults with HIV-1 Infection Shows Primary Efficacy
Merck's Investigational Drug in Treatment-Naive Adults with HIV-1 Infection Shows Primary Efficacy
Nov 19, 2025
07:37 AM EST, 11/19/2025 (MT Newswires) -- Merck ( MRK ) said Wednesday the pivotal phase 3 trial of its investigational regimen of doravirine/islatravir in treatment-naive adults with HIV-1 infection met its success criterion of primary efficacy. Trial topline results showed the non-inferiority of the drug and a comparable safety profile to once-daily oral bictegravir/emtricitabine/tenofovir alafenamide, Merck ( MRK )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved